Stockscreener 앱 받기
49.04
1.98%
-0.99
시간 외 거래:
48.57
-0.47
-0.96%
전일 마감가:
$50.03
열려 있는:
$48.43
하루 거래량:
7.22M
Relative Volume:
0.88
시가총액:
$19.46B
수익:
$2.23B
순이익/손실:
$-3.19B
주가수익비율:
-6.02
EPS:
-8.1462
순현금흐름:
$-1.60B
1주 성능:
-9.77%
1개월 성능:
-9.62%
6개월 성능:
+97.98%
1년 성능:
+107.36%
1일 변동 폭
$47.91
$49.88
1주일 범위
$47.91
$59.48
52주 변동 폭
$22.28
$59.55
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
49.04 | 19.85B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna stock (US60770K1034): pipeline hopes meet volatile share price - AD HOC NEWS
Moderna (MRNA) Rule 144 notice: 53,336 shares proposed via Fidelity on 05/15/2026 - Stock Titan
Moderna stock (US60770K1034): focus on vaccine pipeline after latest earnings - AD HOC NEWS
Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - AOL.com
Moderna stock (US60770K1079): Shares up 71% YTD amid biotech volatility - AD HOC NEWS
Salesforce (CRM), Moderna Partner to Unify Global Operations via Agentforce Life Sciences - Yahoo Finance
Moderna stock (US60770K1034): Q1 2026 net income swings to $169.7M profit - AD HOC NEWS
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Moderna stock (US60770K1034): Ranked #1 on TIME's 2026 Most Impactful Companies - AD HOC NEWS
Still ‘many steps to do’ in creating a hantavirus vaccine, experts say - Global News
Stock market today: S&P 500, Dow futures fall as Trump rejects 'totally unacceptable' Iran peace proposal—Micron Technologies, Moderna in focus - MSN
Moderna stock (US60770K1034): Gains 0.74% to $53.27 on May 12 - AD HOC NEWS
Arbutus Biopharma Q1 revenue surges on Moderna settlement - TradingView
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan
Moderna Is a Money-Losing Vaccine Maker. It’s Also the Ultimate Stock Hedge. - Barron's
Whitefort Capital Management, LP's Moderna Inc(MRNA) Holding History - GuruFocus
Money-Losing Moderna Is a Pandemic Hedge. What to Do With the Stock Now. - Barron's
Moderna (MRNA) Shares Skyrocket, What You Need To Know - Yahoo Finance
Moderna Recognized by TIME as One of the World's Most Impactful Companies - ACCESS Newswire
Why TIME ranked Moderna the world's most impactful company in 2026 - Stock Titan
Transcript : Moderna, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 11 - marketscreener.com
Biotech Stocks Sway Amid Hantavirus Cruise Scare - Investing News Network
Moderna (MRNA) Targets August FDA Decision as mRNA Flu Vaccine Clears Phase 3 Efficacy Bar - AlphaStreet
Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell (NASDAQ:MRNA) - Seeking Alpha
Moderna's Revenues See Strong International Momentum in Q1 Earnings - TradingView
Moderna Inc. stock (US60770K1034): Jumps 8% on hantavirus hype, Q1 earnings beat - AD HOC NEWS
Moderna Updates Bylaws and Confirms Governance Leadership - The Globe and Mail
MODERNA : Jefferies reiterates its Neutral rating - marketscreener.com
Hantavirus outbreak: these 3 stocks are poised to rip higher - Invezz
Hantavirus Fears Fuel Moderna Rally: Is This a Real Catalyst or Just Sentiment? - NAI500
5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call - Yahoo Finance
Moderna reports Q1 loss, stock jumps on strong international sales - MSN
Nvidia, Lumentum, Intel, Micron, Qualcomm, Tesla, Moderna, Circle Internet, and More Movers - Barron's
Key facts: Moderna mRNA hantavirus vaccines; stock up, $74 target - TradingView
Moderna stock pops as investors zero in on hantavirus work following the deadly cruise ship outlook - Business Insider
Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality. - Yahoo Finance
Moderna Stock Loses Steam. Hantavirus Trade Fizzles as Officials Dismiss Pandemic Risk. - Barron's
Moderna (MRNA) Shares Rise Amid Hantavirus Treatment Evaluation - GuruFocus
Moderna Shares Have Rallied. Why the Stock Could Climb Another 30%. - Barron's
Moderna stock (US60770K1034): Shares rally 12% on hantavirus vaccine research - AD HOC NEWS
Moderna (MRNA) Develops Hantavirus Vaccine Amid Low Pandemic Thr - GuruFocus
Moderna’s stock has rallied on hantavirus research that is ‘early-stage’ in nature - MarketWatch
Moderna (MRNA) Stock Rises Amid Hantavirus Outbreak Concerns - GuruFocus
Best Biotech Stocks To Follow NowMay 11th - MarketBeat
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.
Moderna shares extend gains as hantavirus vaccine work draws attention - Proactive financial news
Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging. - Investopedia
Moderna stock soars as hantavirus fears spark outbreak trade - TradingView
Moderna stock (US60770K1034): Q1 earnings beat on revenue, EPS miss sparks gains - AD HOC NEWS
Moderna stock extends gains on hantavirus research - Yahoo Finance
Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax ClimbModerna (NASDAQ:MRNA), Novavax (NAS - Benzinga
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
자본화:
|
볼륨(24시간):